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Abstract
Background: Patients’ perceptions of their illness are dynamic and can directly influence aspects of management.
Our aim was to examine the illness perceptions of gout patients in UK primary care and associations with
allopurinol use.
Methods: A health questionnaire was sent to 1805 people with gout aged ≥18 years identified by a gout diagnosis
or prescriptions for allopurinol or colchicine in their primary care medical records in the preceding 2 years. The
questionnaire included selected items from the revised illness perception questionnaire (IPQ-R). Associations
between illness perceptions and use of allopurinol were calculated using multinomial logistic regression adjusted
for age, gender, deprivation status, body mass index, alcohol consumption, comorbidities and gout characteristics.
Results: One thousand one hundred eighty-four participants responded to the baseline questionnaire (65.6 %).
Approximately half of responders perceived that they were able to control (51.2 %) or affect their gout through
their own actions (44.8 %). Three quarters perceived treatments to be effective (76.4 %) and agreed that gout is a
serious condition (76.4 %). Patients who agreed that they could control their gout (Relative Risk Ratio, 95 %
confidence interval 1.66 (1.12 to 2.45)) and that treatments were effective (2.24 (1.32 to 3.81)) were more likely to
currently be using allopurinol than not using allopurinol. However, this significance was attenuated after adjustment
for self-reported gout characteristics (1.39 (0.89 to 2.17) & 1.78 (0.96 to 3.29) respectively).
Conclusions: Patients who perceive that they can control their gout and that treatments are effective are more
likely to be using allopurinol, this suggests that better information is needed for the patient from GPs and
rheumatologist to reassure and support their use of ULT.
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Background
Gout is the most prevalent form of inflammatory arth-
ritis, affecting 2.5 % of adults [1]. Gout is primarily
attributed to hyperuricemia, the saturation of urate in
and around the joints and connective tissues. Deposition
of mono-sodium urate (MSU) crystals then leads to attacks
of acute gout, tophi and progressive joint damage [2].
Long-term treatment of gout is achieved through
urate-lowering therapies (ULT), such as allopurinol,
which is the recommended drug for initial lowering of
serum urate (sUA). Once target sUA levels have been
reached, allopurinol use should be continued throughout
life, to maintain sUA levels [3]. Despite these clear
guidelines, primary care management of gout is typically
sub-optimal in primary care [1].
When individuals are diagnosed with a chronic condi-
tion, such as gout, they will develop organised patterns
of beliefs in response. Depending on how the individual
perceives this new illness, these can directly influence
aspects of management, such as drug adherence, but
such illness perceptions are also dynamic and can alter
[4]. Illness perceptions can be measured through rating
and assessment of questionnaire statements related to
the impact of illness on the individual, such as the ‘Re-
vised Illness Perception Questionnaire’ (IPQ-R) [5].
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Responses measure how the individual components of
illness perception, for example Identity (Is illness central
to how the individual identifies themselves?), Cause
(How the disease arose?), interact to form the patient’s
overall opinion regarding their chronic condition [6].
How one interprets the individual components forms an
overall illness perception [7].
Illness perceptions are dynamic, with the potential to
change depending on alterations in beliefs. Perceptions
may change due to internal factors (e.g. beliefs about
disease control) or external factors (e.g. effects of medi-
cation) and can potentially result in changes to disease
outcomes [8]. De Gucht [9] found the relationship be-
tween irritable bowel symptom severity and separate
quality of life dimensions to be fully mediated by illness
perceptions. Dissatisfaction with treatment can manifest
in follow-up consultations and lead to reduced adher-
ence to treatment, leading to poorer disease outcomes
[10]. Conversely an alteration in thoughts and emotions
can also improve outcomes [4].
The relationship between illness perceptions and disease
outcomes in gout has only previously been examined in a
single study. Dalbeth et al. recruited 142 patients from pri-
mary and secondary care in New Zealand who completed
the Brief Illness Perception Questionnaire (B-IPQ) and
Health Assessment Questionnaire (HAQ II), at baseline
and 1-year follow up. Participants who had poorer illness
perceptions had an increased likelihood of disease pro-
gression and poorer adherence to ULT, suggesting that
identification of such illness perceptions in clinical prac-
tice could be important to potentially identify those at risk
of worse outcome [8]. However, the small sample size
used in the Dalbeth et al. paper and the inclusion of
secondary care patients, who would be likely to have more
severe disease and hence different illness perceptions, are
unlikely to be comparable to gout patients from UK pri-
mary care. 25 % of participants had tophi, which is more
than typically seen in UK primary care.
There is presently little data on the illness perceptions
of gout patients. Therefore, the aim of this cross-sectional
analysis was to examine the illness perceptions of gout
patients from UK primary care, with the specific objective
to examine the associations between illness perceptions
and the current use of allopurinol.
Methods
Study design and population
In 2012, as part of a longitudinal cohort study, a baseline
questionnaire was mailed to 1805 gout patients, aged
18 years of age and older, registered with 20 general
practices. Gout was defined by a history of previous gout
consultation or a prescription of allopurinol or colchicine
within the 2 years, identified in primary care medical re-
cords, prior to completing the baseline questionnaire [11].
This paper will describe cross-sectional analysis of base-
line data from the cohort study. This study was approved
by the North West - Liverpool East Research Ethics
Committee (Ref no: 12/NW/0297).
Survey measures
At baseline, characteristics recorded through the self-
report questionnaire included age, gender, and body
mass index (BMI), calculated from self-reported height
and weight. Indices of Multiple Deprivation (IMD) were
used to quantify deprivation status and categorise indi-
viduals into tertiles of; 20 % least affluent, 20 % most
affluent and middle 60 %. We also recorded participants’
alcohol consumption.
Several gout specific characteristics were assessed,
including; number of gout attacks in the previous
12 months, history of attacks of gout affecting more than
one joint (oligo/polyarticular attacks), age at gout diagno-
sis, whether participants were currently experiencing a
gout attack and whether they were currently taking
allopurinol. Self-reported comorbidities were recorded, in-
cluding; hypertension, transient ischaemic attack, anxiety,
myocardial infarction, hyperlipidaemia, kidney stones and
type II diabetes mellitus. The prevalence and severity of
anxiety and depression were each recorded using a
specific disease outcome, the generalised anxiety disorder
(GAD-7) and patient health questionnaire (PHQ-9),
respectively.
Questions were selected from the Revised Illness
Perception Questionnaire (IPQ-R) [5], with participants
answering several questions related to gout, comprising;
i) there is a lot I can do to control my gout?, ii) what I do
will affect my gout?, iii) treatments are effective?, iv) gout
is serious?, in order to determine illness perceptions and
patient understanding of disease.
Statistical analysis
The characteristics of the study sample were initially
summarised using descriptive statistics. The mean age
(standard deviation (SD)) and gender were reported.
BMI was categorised by those with a score <25 kg/m2
(healthy weight) or ≥25 kg/m2 (overweight). The fre-
quency with which alcohol was consumed was categorised
as; i) never, ii) occasionally, iii) 1–3 times per month, iv)
1–2 times a week, v) 3–4 times a week or vi) daily/almost
daily. For gout-specific characteristics, number of gout
attacks in the preceding 12 months was categorised into i)
0 gout attacks, ii) 1–3 gout attacks, iii) ≥4 gout attacks.
History of oligo/polyarticular attacks and allopurinol use
were categorised as yes or no. Possible IPQ-R responses
were strongly agree, agree, uncertain, disagree or strongly
disagree to the four statements. ‘Strongly agree’ and
‘Agree’ were combined into a single category (‘Agree’) and
‘Strongly disagree’ and ‘Disagree’ into a single category
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‘Disagree’. Collapsing of categories was performed, boost-
ing the number of responses in each of the three
remaining categories and reducing extreme differences in
response numbers between individual categories for each
question.
Associations between the samples’ characteristics and
the use of allopurinol were initially compared using in-
dependent t-test or chi-squared test (χ2). Multinomial
logistic regression was used to identify associations
between the use of allopurinol and IPQ-R responses, re-
ported as relative risk ratios (RRR) with 95 % confidence
intervals (95 % CI). After initial unadjusted analysis,
RRR were adjusted for the sample characteristics of age,
gender and deprivation status, BMI, alcohol consump-
tion and comorbidities. The choice of these relating to
their association with illness perceptions [8, 12] and gout
[13, 14]. A subsequent adjustment was then made for
gout characteristics, an important confounder likely to
influence patients’ perceptions of their illness [8]. Gout
characteristic included; the number of gout attacks in
previous 12 months, history of oligo/polyarticular attacks,
age at gout diagnosis and whether currently experiencing
a gout attack.
Model diagnostics such as Nagelkerke’s Pseudo R2 and
Pearson goodness-of- fit values are reported for the
latter models in order to show that the models are a
reasonable approximation of the data. Nagelkerke’s R-
squared reflects the change in terms of log-likelihood
from the intercept-only model to the current model. It
does not convey the same information as the R-square
for linear regression. All analyses were undertaken using
SPSS v.21.
Results
Sample characteristics
Detailed characteristics of this sample have been re-
ported elsewhere [15], but in brief, the 1184 responders
to the baseline questionnaire (65.6 %) had a mean age of
65.6 years (SD = 12.5), the majority were male (83.6 %)
and classified as overweight or obese (68.7 %). Nearly a
quarter of participants drank alcohol on a daily basis
(23.4 %) and the most prevalent comorbidities were
hypertension (61.7 %), and hyperlipidaemia (42.9 %)
(Table 1).
The average age at which gout had been diagnosed
was 53.4 years (SD 15.9) and 725 (64.5 %) patients had
experienced at least one gout attack in the previous
12 months. One hundred thirty-two patients (11.1 %)
were experiencing an attack of gout at the time of com-
pleting the baseline questionnaire and 436 (36.8 %) had
a history of oligo/polyarticular attacks. Just over half of
baseline responders (56.3 %) were using allopurinol
(Table 2). When stratified by allopurinol use, there was no
difference in age, alcohol consumption, social deprivation
or the prevalence of anxiety, depression, stroke, TIA, kid-
ney stones or MI between users and non-users. However,
allopurinol users were more likely than non-users to be
overweight (χ2 = 4.70, df =1120 p = .030) and to have dia-
betes (χ2 (1, N = 1120) = 17.67, p = <0.001), hypertension
(χ2 = 11.16, df =1120, p = .010), hyperlipidaemia (χ2 = 6.19,
df = 1120, p = .013), kidney stones (χ2 = 5.17, df = 1120,
p = .023) and angina (χ2 = 4.04, df = 1120, p = .044).
With regard to illness perceptions, approximately
half of all participants agreed that there is either a lot
they can do to control their gout (51.2 %) or that
what they do will affect their gout (44.8 %). Three-
quarters of gout patients perceived treatments to be
effective (76.4 %) and agreed that gout is a serious
condition (76.4 %).
Table 1 General characteristics
Using allopurinol
Factor Frequency (%) No (%) Yes (%)
Age Mean (SD) 65.6 (12.5) 65.1 (13.4) 65.9 (11.6)
Gender (Male %) 990 (83.6) 390 (79.6) 544 (86.4)
Alcohol Consumption
Never 113 (9.7) 50 (10.4) 56 (9.0)
Occasionally 155 (13.3) 63 (13.1) 86 (13.8)
1–3 times per month 109 (9.3) 47 (9.8) 57 (9.0)
1–2 times per week 254 (21.8) 110 (22.9) 129 (20.6)
3–4 times per week 263 (22.5) 102 (21.3) 148 (23.7)
Daily 273 (23.4) 108 (22.5) 149 (23.8)
Body Mass Index
Normal (<25 kg/m2) 371 (31.3) 168 (34.3) 178 (28.2)
Overweight/obese
(≥25 kg/m2)
813 (68.7) 322 (65.7) 452 (71.8)
Neighbourhood Deprivation Status
20 % least deprived 410 (34.6) 174 (35.5) 214 (34.0)
Mid-deprived 405 (34.2) 160 (32.7) 228 (36.2)
20 % most deprived 369 (31.2) 156 (31.8) 188 (29.8)
Depression (PHQ-9) 131 (11.1) 46 (11.0) 76 (13.4)
Anxiety (GAD-7) 109 (10.0) 42 (9.3) 59 (10.0)
Type II Diabetes Mellitus 205 (17.3) 60 (12.2) 138 (21.9)
Stroke 37 (3.1) 12 (2.5) 24 (3.8)
Hypertension 731 (61.7) 274 (55.9) 414 (65.7)
Transient Ischaemic Attack 62 (5.2) 24 (4.9) 34 (5.4)
Hyperlipidaemia 508 (42.9) 190 (38.8) 291 (46.2)
Kidney Failure 56 (4.7) 18 (3.7) 31 (4.9)
Myocardial Infarction 119 (10.1) 44 (9.0) 67 (10.6)
Kidney Stones 81 (6.8) 23 (4.7) 51 (8.1)
Angina 147 (12.4) 49 (10.0) 88 (14.0)
SD standard deviation, PHQ-9 personalised health questionnaire-9, GAD-7
generalised anxiety disorder 7 questionnaire
Walsh et al. BMC Musculoskeletal Disorders  (2016) 17:394 Page 3 of 6
Participants using allopurinol were diagnosed with gout
at a younger mean age (50.6 years, SD 15.5) compared to
non-users (57.3 years, SD 15.5), t (1076) = −7.11, p < 0.001
(Table 2). Allopurinol users were significantly less likely to
have experienced one or more attacks of gout in the
preceding 12 months (51.8 % versus 80.2 %) (χ2 = 95.63,
df = 1103, p <0.001), but more likely to have a history of
oligo/polyarticular attacks (45.3 % versus 29.0 %) than
non-users (χ2 = 30.93, df =1103, p <0.001).
Associations between illness perceptions and use of
allopurinol
Unadjusted analysis showed that gout patients were
more likely to agree (1.64 (1.14 to 2.34)) than disagree,
with the statement that there is ‘a lot I can do to control
my gout’ when using allopurinol. This association was
retained after initial adjustments (1.66 (1.12 to 2.45), but
was attenuated after adjustments for gout characteristics
(1.39 (0.89 to 2.17) (Table 3).
Gout patients were twice as likely to agree than dis-
agree (unadjusted 2.20 (1.36 to 3.54), adjusted 2.24 (1.32
to 3.81)) that ‘treatments are effective’ if they were using
allopurinol. However, this association was also attenu-
ated when gout characteristics were adjusted for (1.78
(0.96 to 3.29). Both unadjusted and adjusted analysis
showed no significant difference between the patient
perception of ‘What I do will affect my gout’ or that
“Gout is serious” and their current use of allopurinol.
The Pearson goodness of fit p-values provided no real
cause for concern, except the borderline result for the
Table 2 Gout characteristics
Using allopurinol
Characteristics Frequency (%) No (%) Yes (%)
Age at Gout Diagnosis
(Mean, SD)
53.4 (15.9) 57.3 (15.5) 50.6 (15.5)
Number of attacks in previous 12 months
0 398 (35.4) 96 (19.8) 298 (48.2)
1–3 521 (46.4) 253 (52.2) 163 (26.4)
≥4 204 (18.2) 136 (28.0) 157 (25.4)
Gout Attack at Present 132 (11.1) 54 (11.1) 69 (11.0)
History of oligo/Polyarticular
gout
436 (36.8) 141 (29.0) 283 (45.3)
Currently Taking Allopurinol
Yes 630 (56.3) - -
No 490 (43.7) - -
Table 3 Associations between Illness perceptions and allopurinol use
Using allopurinol Adjusted relative risk ratio (RRR) (95 % CI)
Yes (%) No (%) Unadjusted RRR (95 % CI) Age, gender, deprivation, BMI,
alcohol & co-morbidities
Age, gender, deprivation, BMI,
alcohol, co-morbidities & gout
characteristics
A lot I can do to control my gout
Disagree (N = 154) 78 (12.7) 76 (16.2) REF REF REF
Uncertain (N = 375) 190 (30.8) 185 (39.5) 1.00 (0.69 to 1.46) 1.01 (0.67 to 1.51) 1.10 (0.70 to 1.73)
Agree (N = 555) 348 (56.5) 207 (44.3) 1.64 (1.14 to 2.34) 1.66 (1.12 to 2.45) 1.39 (0.89 to 2.17)
Nagelkerke r2, Pearson GOF 0.094, p = 0.053 0.18, p = 0.43
What I do will affect my gout
Disagree (N = 104) 64 (10.5) 40 (8.5) REF REF REF
Uncertain (N = 487) 264 (43.3) 233 (49.4) 0.74 (0.48 to 1.14) 0.66 (0.41 to 1.04) 0.74 (0.44 to 1.23)
Agree (N = 480) 281 (46.2) 199 (42.1) 0.88 (0.57 to 1.36) 0.82 (0.51 to 1.31) 0.69 (0.41 to 1.16)
Nagelkerke r2, Pearson GOF 0.07, p = 0.65 0.12, p = 0.91
Treatments are effective
Disagree (N = 75) 32 (5.2) 43 (9.3) REF REF REF
Uncertain (N = 180) 73 (11.8) 107 (23.1) 0.92 (0.53 to 1.58) 0.98 (0.54 to 1.79) 1.06 (0.54 to 2.06)
Agree (N = 827) 513 (83.0) 314 (67.6) 2.20 (1.36 to 3.54) 2.24 (1.32 to 3.81) 1.78 (0.96 to 3.29)
Nagelkerke r2, Pearson GOF 0.12, p = 0.11 0.29, p = 0.54
Gout is serious
Disagree (N = 63) 33 (5.3) 30 (6.4) REF REF REF
Uncertain (N = 195) 98 (15.8) 97 (20.6) 0.92 (0.52 to 1.62) 0.79 (0.42 to 1.50) 0.91 (0.43 to 1.89)
Agree (N = 834) 490 (78.9) 344 (73.0) 1.29 (0.78 to 2.16) 1.15 (0.65 to 2.05) 1.15 (0.59 to 2.26)
Nagelkerke r2, Pearson GOF 0.09, p = 0.39 0.12, p = 0.96
Bold: p = <0.05. GOF goodness-of-fit
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first adjusted model for ‘a lot I can do to control my
gout’. Nagelkerke’s R-squared are quite low suggesting
other variables might need to be recorded.
Discussion
Our study examined the illness perceptions of gout
patients from UK primary care and the associations be-
tween these perceptions and the current use of allopur-
inol. The majority of gout patients perceive that gout is
a serious condition and that treatments are effective, but
only half of patients believe that their actions have any
influence over their own condition. Gout patients who
feel more in control of their own condition and perceive
treatments to be effective are more likely to be current
users of allopurinol than non-users. Despite these associ-
ations being attenuated by gout characteristics, such
links between illness perceptions and use of allopurinol
remain worthy of reporting as this is likely an over-
adjustment, due to the close associations between illness
perceptions, use of allopurinol and severity of gout.
Our overall findings that patients perceived gout to be
a chronic condition that can be managed with treatment,
but for which personal actions have little influence are
in-line with those of Dalbeth et al. [8]. Furthermore,
Dalbeth et al. also reported issues between the percep-
tion of control and ULT, as patients who had concerns
over ULT had less ability to control their disease and re-
corded higher symptomatic scores in the B-IPQ. This
may be reflected in our findings that those who perceived
less control of their gout were less likely to be using
allopurinol.
Two key factors which impair the effectiveness of allo-
purinol are poor adherence and sub-optimal dosing to
sufficiently lower urate levels [1]. Informing and empow-
ering patients in the control of their own disease may
improve subsequent managements, such as use of allo-
purinol [16]. It is clear that patients need to be better
informed of the long-term benefits of allopurinol, such
as preventing irreversible joint damage and complications
associated with comorbidities [17].
The strengths of this study are that this uses a large
sample of gout patients from UK primary care, adding
to the limited data of illness perceptions in gout patients.
This also builds on research examining the current role
of allopurinol in UK primary care.
Limitations of this study include the use of only four
IPQ-R questions from the responder questionnaire;
however, these questions were selected on the basis that
they most appropriately represented patient perceptions
of gout and ULT, based on our previous qualitative re-
search with gout patients [18]. One of these IPQ-R ques-
tions refers to treatment, but does not mention
allopurinol or ULT specifically. In determining the percep-
tions of treatments in allopurinol users, we have assumed
that patients taking allopurinol answered the treatment
question with this in mind, rather than other treatments.
As we specifically asked patients whether they were “cur-
rently taking a tablet called allopurinol”, then it is likely
that this is their principal treatment (as guidelines recom-
mend) and that they were at least adhering at the point of
the baseline questionnaire. The vast majority of ULT users
in primary care in the UK are prescribed allopurinol, with
other ULTs (febuxostat and uricosurics) comprising less
than 2 % of prescriptions for ULT in 2015 [19]. Whilst we
believe that any perceptions about ULT will relate to allo-
purinol, we did not quantify use of, or ask about percep-
tions of other drugs such as colchicine or NSAIDs. We
are also unable to determine whether the reasons behind
non-allopurinol use are related to patient (e.g. poor adher-
ence) or practitioner reasons (e.g. lack of provision by the
general practitioner (GP)). Finally, our findings may be an
effect of confounding by indication. It is likely that those
prescribed allopurinol have the most severe gout, sup-
ported by our finding that allopurinol users more fre-
quently reported experiencing oligo/polyarticular attacks
in the past than non-users. Therefore, allopurinol may be
acting as a proxy for increased disease severity.
Improved gout characteristics, be this due to allopurinol
use or not, are the desired goals. If patients perceive that
they are able to control and treat their disease, this may
encourage improved adherence and continued optimal
management. In light of these findings and that only half
(53.2 %) of this gout sample were using allopurinol, the
key clinical implication of our findings is a need to ensure
that clinicians are appropriately trained to discuss the use
of ULT with patients, and that patients are given high-
quality information to aid their understanding of the ben-
efits of ULT and importance of adherence to treatment.
Conclusions
In conclusion, gout patients in UK primary care under-
stand the seriousness of their condition and that treat-
ments are effective, but perceive little personal control of
their condition. Gout patients who viewed gout treat-
ments as effective and did perceive a sense of control were
more likely to be currently using allopurinol. Therefore,
better information is needed for the patient, from GPs and
rheumatologist, to encourage a sense of control over one’s
condition with the aim improving health outcomes.
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